Abstract Surgeons increasingly use robot-assisted minimally invasive surgery for a variety of medical conditions. For hospitals, the acquisition and maintenance of a robot requires a significant investment, but financial returns are not linked to any improvement in long-term patient outcomes in the current reimbursement environment. Kidney cancer provides a useful case study for evaluating the long-term value that this innovation can provide. Kidney cancer is generally treated through partial or radical nephrectomy, with evidence favoring the former procedure for appropriate patients. We found that robot-assisted surgeryincreased access to partial nephrectomy and that partial nephrectomy reduced mortality and renal failure. The value of the benefits of robot-assisted minimally invasive surgery to patients, in terms of quality-adjusted life-years gained, outweighed the health care and surgical costs to patients and payers by a ratio of five to one. In addition, we found no evidence that the availability of robot-assisted minimally invasivesurgery increased the likelihood that inappropriate patients received partial nephrectomy. Project HOPE—The People-to-People Health Foundation, Inc.
Health Affairs
2015
Chandra A, Snider JT, Wu Y, Jena A, Goldman DP
http://www.ncbi.nlm.nih.gov/pubmed/?term=robot%20assisted%20surgery%20for%20kidney%20cancer%20increased%20access%20to%20a%20procedure%20that%20can%20reduce%20mortality%20and%20renal%20failure